Cargando…

Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis

INTRODUCTION: Adalimumab, a humanized monoclonal antibody targeted against TNF-α, has proved to be successful in the treatment of uveitis. Another anti-TNF-α agent, i.e., infliximab, has been reported of benefit in the treatment of refractory sarcoidosis. The aim of this prospective case series was...

Descripción completa

Detalles Bibliográficos
Autores principales:	Erckens, R. J., Mostard, R. L. M., Wijnen, P. A. H. M., Schouten, J. S., Drent, M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer-Verlag 2011
Materias:	Inflammatory Disorders
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3332360/ https://www.ncbi.nlm.nih.gov/pubmed/22119879 http://dx.doi.org/10.1007/s00417-011-1844-0

Ejemplares similares

New onset of acute uveitis following COVID-19 vaccination
por: Sim, Ha Eun, et al.
Publicado: (2022)

Relevance of erythrocyte sedimentation rate and C-reactive protein in patients with active uveitis
por: Groen-Hakan, Fahriye, et al.
Publicado: (2018)

A new look into uveitis in Colombia: changes in distribution patterns and clinical characteristics over the last 25 years
por: Polanía, Diego, et al.
Publicado: (2022)

Fluocinolone acetonide 0.19-mg implant for the treatment of noninfectious uveitis with involvement of the posterior segment: a real-world study
por: Buhl, Lara, et al.
Publicado: (2022)

Successful treatment of blepharitis with bibrocathol (Posiformin(®) 2 %)
por: Bezdetko, Pavel A., et al.
Publicado: (2012)

Elevated percentage of HLA-DR(+) and ICAM-1(+) conjunctival epithelial cells in active Graves’ orbitopathy
por: Pawlowski, P., et al.
Publicado: (2014)

Cytomegalovirus-positive Posner-Schlossman syndrome: to compare differences in retinal vessel area density between the affected and non-affected eye using optical coherence tomography angiography
por: Hülse, Patricia, et al.
Publicado: (2023)

CCL20/MIP-3 alpha mRNA expression in the conjunctival epithelium of normal individuals and patients with vernal keratoconjunctivitis
por: Inada, Noriko, et al.
Publicado: (2014)

Evaluation of the retinal, choroidal, and nerve fiber layer thickness changes in patients with toxic anterior segment syndrome
por: Sorkin, Nir, et al.
Publicado: (2014)

Diagnostic efficacy of real-time PCR for ocular cytomegalovirus infections
por: Miyazaki, Dai, et al.
Publicado: (2018)

Conjunctivitis in COVID-19 patients: frequency and clinical presentation
por: Güemes-Villahoz, Noemi, et al.
Publicado: (2020)

Posterior ocular structural and vascular alterations in severe COVID-19 patients
por: Bayram, Nurettin, et al.
Publicado: (2021)

Histopathological assessments reveal retinal vascular changes, inflammation, and gliosis in patients with lethal COVID-19
por: Jidigam, Vijay K., et al.
Publicado: (2021)

Decrease of choriocapillary vascular density measured by optical coherence tomography angiography in Vogt-Koyanagi-Harada disease
por: Liang, Anyi, et al.
Publicado: (2021)

Relationship among total tear IgE, specific serum IgE, and total serum IgE levels in patients with pollen-induced allergic conjunctivitis
por: Yamana, Yasuo, et al.
Publicado: (2021)

Association between HPV detection in swab samples and tissue specimens and ophthalmic pterygium recurrence
por: Chalkia, Aikaterini K., et al.
Publicado: (2021)

Quantitative evaluation of lipid layer thickness and blinking in children with allergic conjunctivitis
por: Yang, Boyu, et al.
Publicado: (2021)

Analysis of microvascular and neurodegenerative complications of mild COVID-19
por: Kolkedi, Zsofia, et al.
Publicado: (2022)

Management of autoimmune retinopathy treated with intravitreal dexamethasone implant
por: Hou, Si-Meng, et al.
Publicado: (2022)

Adalimumab for the treatment of fistulas in patients with Crohn’s disease
por: Colombel, J-F, et al.
Publicado: (2009)

Outcome of adalimumab monotherapy in paediatric non-infectious uveitis
por: Al-Julandani, DA, et al.
Publicado: (2023)

The Effect of Adalimumab in Korean Patients with Refractory Noninfectious Uveitis
por: Park, Sung Eun, et al.
Publicado: (2021)

Superior efficacy of Adalimumab in treating childhood refractory chronic uveitis when used as first biologic
por: Simonini, G, et al.
Publicado: (2011)

Adalimumab maintains remission of Crohn's disease after up to 4 years of treatment: data from CHARM and ADHERE
por: Panaccione, R, et al.
Publicado: (2013)

Efficacy of adalimumab in sarcoidosis
por: Kamphuis, LSJ, et al.
Publicado: (2010)

Intraocular Inflammation Control and Changes in Retinal and Choroidal Architecture in Refractory Non-Infectious Uveitis Patients after Adalimumab Therapy
por: Pirani, Vittorio, et al.
Publicado: (2020)

Usefulness of Adalimumab in the Treatment of Refractory Uveitis Associated with Juvenile Idiopathic Arthritis
por: García-De-Vicuña, Carmen, et al.
Publicado: (2013)

Autoinflammatory granulomatous diseases: from Blau syndrome and early-onset sarcoidosis to NOD2-mediated disease and Crohn's disease
por: Caso, Francesco, et al.
Publicado: (2015)

Superior efficacy of Adalimumab in treating childhood refractory chronic uveitis when used as first biologic modifier drug: Adalimumab as starting anti-TNF-α therapy in childhood chronic uveitis
por: Simonini, Gabriele, et al.
Publicado: (2013)

A predictive tool for an effective use of (18)F-FDG PET in assessing activity of sarcoidosis
por: Mostard, Rémy LM, et al.
Publicado: (2012)

Tight control for Crohn’s disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial
por: Panaccione, Remo, et al.
Publicado: (2020)

Treatment persistence and colectomy-free outcomes in patients with ulcerative colitis receiving golimumab or adalimumab: a UK experience
por: Hoque, Sami, et al.
Publicado: (2020)

Uveitis in sporadic Blau syndrome: Long-term follow-up of a refractory case treated successfully with adalimumab
por: Naik, Anmol U, et al.
Publicado: (2018)

Four-Year Maintenance Treatment With Adalimumab in Patients with Moderately to Severely Active Ulcerative Colitis: Data from ULTRA 1, 2, and 3
por: Colombel, Jean-Frederic, et al.
Publicado: (2014)

Cost-effectiveness of adalimumab, infliximab or vedolizumab as first-line biological therapy in moderate-to-severe ulcerative colitis
por: Yokomizo, Lauren, et al.
Publicado: (2016)

Efficacy of adalimumab in patients with Crohn's disease and symptomatic small bowel stricture: a multicentre, prospective, observational cohort (CREOLE) study
por: Bouhnik, Yoram, et al.
Publicado: (2018)

Efficacy and safety of adalimumab in the treatment of non-infectious uveitis: a meta-analysis and systematic review
por: Ming, Shuai, et al.
Publicado: (2018)

Comparison of infliximab with adalimumab for the treatment of non-infectious uveitis: a systematic review and meta-analysis
por: Liu, Weishai, et al.
Publicado: (2023)

Refractory necrotizing scleritis successfully treated with adalimumab
por: Lawuyi, Lola E., et al.
Publicado: (2016)

Efficacy of adalimumab in refractory juvenile idiopathic arthritis related uveitis: report of 6 cases
por: Vougiouka, O, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_db39ttt7g1nks9u9ud0mmeoeq9